公开(公告)号：US20240203593A1

公开(公告)日：2024-06-20

申请号：US18537992

申请日：2023-12-13

Applicant: IMMUNOBIOME INC.

Inventor： Seung Yeon CHOI ,  In Hae KIM ,  Jung Hwan PARK ,  Ju Hun LEE

IPC: G16H50/20 ,  G16B20/00 ,  G16B40/20

CPC classification number: G16H50/20 ,  G16B20/00 ,  G16B40/20

Abstract: The present invention aims to discover a microbial cluster that can be used when developing effective probiotics for a specific disease. Specifically, the invention includes (1) discovering a candidate microbial cluster data related to specific disease, which is collected by preprocessing a gut microbiota data (a taxonomy abundance table) and (2) training the machine learning model using the collected candidate microbial cluster data, and selecting a model with the highest predictive performance to discover a disease-microbial consortium.

公开(公告)号：US20220370525A1

公开(公告)日：2022-11-24

申请号：US17811542

申请日：2022-07-08

Applicant: IMMUNOBIOME INC.

Inventor： Sin-Hyeog IM ,  Garima SHARMA ,  Sun-Hee PARK ,  Amit SHARMA

IPC: A61K35/747 ,  C12N1/20 ,  A23L33/135 ,  A61P35/00

Abstract: The present invention relates to a novel Lactobacillus plantarum IMB19 strain, polysaccharides derived from the strain, and a use thereof. A novel Lactobacillus plantarum IMB19 strain and polysaccharides derived from the strain of the present invention exhibit an excellent CD8+T cell activity stimulating ability and Treg cell inhibitory activity, and stimulate and improve an antitumor immune response through various mechanisms such as increased macrophage infiltration in CPS tumors and differentiation and reprogramming of macrophages into an inflammatory phenotype (M1). Therefore, a strain and polysaccharides derived from the strain of the present invention can be effectively used for immune regulation, especially immune boosting, in a subject, and can inhibit tumor growth by inducing and enhancing an antitumor immune response. A novel strain and polysaccharides derived from the strain of the present invention are useful in the prevention, alleviation or treatment of such as tumors, infectious diseases and various immune diseases that are the cause of or symptom of immune dysfunction.

公开(公告)号：US20250025521A1

公开(公告)日：2025-01-23

申请号：US18577252

申请日：2022-07-07

Applicant: IMMUNOBIOME INC. ,  POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION

Inventor： Sin-Hyeog IM ,  Garima SHARMA ,  Amit Kumar SHARMA ,  Sunhee PARK

IPC: A61K35/747 ,  A61K31/715 ,  A61K35/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention relates to a combination use of a novel Lactobacillus plantarum IMB19 strain and/or polysaccharides derived from the strain with an anticancer drug for preventing or treating tumors. The novel Lactobacillus plantarum IMB19 strain and polysaccharides derived from the strain of the present invention exhibit an excellent ability to stimulate CD8+T cell activity and exhibit excellent Treg cell inhibitory activity, and stimulate and improve antitumor immune response through various mechanisms such as increased macrophage infiltration in CPS tumors and differentiation and reprogramming of macrophages into an inflammatory phenotype (M1). Furthermore, the strain and the polysaccharides may significantly increase antitumor immune response when administered in combination with an anticancer drug, particularly an immuno-anticancer drug such as a PD-1 or PD-L1 inhibitor (e.g., a PD-1 antibody, a PD-L1 antibody, or the like), and exhibit a remarkable tumor growth suppression effect compared to the case of using the anticancer drug alone. Therefore, the present invention can be effectively used to prevent, relieve, or treat tumors through administration in combination with various anticancer drugs.

公开(公告)号：US11690884B2

公开(公告)日：2023-07-04

申请号：US17811542

申请日：2022-07-08

Applicant: IMMUNOBIOME INC.

Inventor： Sin-Hyeog Im ,  Garima Sharma ,  Sun-Hee Park ,  Amit Sharma

IPC: A61K35/747 ,  A23L33/135 ,  A61P35/00 ,  C12N1/20 ,  C12R1/25

CPC classification number: A61K35/747 ,  A23L33/135 ,  A61P35/00 ,  C12N1/205 ,  C12R2001/25

Abstract: The present invention relates to a novel Lactobacillus plantarum IMB19 strain, polysaccharides derived from the strain, and a use thereof. A novel Lactobacillus plantarum IMB19 strain and polysaccharides derived from the strain of the present invention exhibit an excellent CD8+T cell activity stimulating ability and Treg cell inhibitory activity, and stimulate and improve an antitumor immune response through various mechanisms such as increased macrophage infiltration in CPS tumors and differentiation and reprogramming of macrophages into an inflammatory phenotype (M1). Therefore, a strain and polysaccharides derived from the strain of the present invention can be effectively used for immune regulation, especially immune boosting, in a subject, and can inhibit tumor growth by inducing and enhancing an antitumor immune response. A novel strain and polysaccharides derived from the strain of the present invention are useful in the prevention, alleviation or treatment of such as tumors, infectious diseases and various immune diseases that are the cause of or symptom of immune dysfunction.

公开(公告)号：US20240290455A1

公开(公告)日：2024-08-29

申请号：US18631165

申请日：2024-04-10

Applicant: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION ,  IMMUNOBIOME INC.

Inventor： Sang Uk KIM ,  Jung Ho KONG ,  In Hae KIM ,  Chang Wook Park

IPC: G16H20/17 ,  G16B20/30 ,  G16H50/70

CPC classification number: G16H20/17 ,  G16B20/30 ,  G16H50/70

Abstract: The present disclosure is to provide a biomarker-searching method that can predict responses to ICI treatment and overall survival of ICI-treated patients. When the device and the method according to the present disclosure are used, it is possible to detect a biomarker capable of accurately predicting effectiveness of ICI treatment on cancer patients and overall survival of the cancer patients. Accordingly, it is possible to maximize the effectiveness of ICI treatment.

公开(公告)号：US20240212786A1

公开(公告)日：2024-06-27

申请号：US18537930

申请日：2023-12-13

Applicant: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION ,  IMMUNOBIOME INC.

Inventor： Kwang Hwan LEE ,  Sang Uk KIM ,  In Hae KIM ,  Ju Hun LEE

IPC: G16B15/30 ,  G16B25/10

CPC classification number: G16B15/30 ,  G16B25/10

Abstract: In the present disclosure, the present inventors validated the effectiveness of the co-essentiality network, constructed from the gene essentiality profile across cancer cells, as a robust platform for identifying anticancer targets. Furthermore, the co-essentiality network facilitated the drug repurposing not previously addressed by conventional molecular networks. These findings underline the value of co-essentiality networks in advancing precision oncology, offering new potential therapeutic avenues.

公开(公告)号：US20240153635A1

公开(公告)日：2024-05-09

申请号：US18447458

申请日：2023-08-10

Applicant: IMMUNOBIOME INC. ,  POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION

Inventor： Sang Uk KIM ,  Min Hyuk Park ,  In Hae KIM ,  Chang Wook Park

IPC: G16H50/20 ,  G16B15/30 ,  G16B25/10 ,  G16H10/20 ,  G16H70/40

CPC classification number: G16H50/20 ,  G16B15/30 ,  G16B25/10 ,  G16H10/20 ,  G16H70/40

Abstract: According to the present disclosure, it is possible to predict a success or a failure of a clinical trial by reflecting the effect of a drug on a cell population and a human gene. Therefore, it is possible to solve the problems caused by excessive clinical trials, such as excessive use of the drug.